Cited by 6,683PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J., Hickson, Ian, Knights, Charlotte, Martin, Niall M. B., Jackson, Stephen P., Smith, Graeme C. M., Ashworth, Alan·2005·Nature

DOI 10.1038/nature03445

Open this paper in CoChat — free account

Abstract

BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.

Integrity signals

Registry

Crossref · 10.1038/nature03445

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citation
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,007
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T. H., Murcia, J. M., & de MURCIA, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 744
Breast and Ovarian Cancer
Wooster, R., & Weber, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 619
The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin
Bhattacharyya, A., Ear, U., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 584
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes
Furuta, T., Takemura, H., Liao, Z.-Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300198200 · Cited by 449

Show all 24 references

Sorted by citations

Items 201–300 of 1,042

The Fanconi Anemia/BRCA pathway: new faces in the crowdPreprint
Kennedy, R. D., & D’Andrea, A. D. (2005) · Genes & Development · doi:10.1101/gad.1370505 · Cited by 471
Methylating Agents and DNA Repair Responses: Methylated Bases and Sources of Strand Breaks
Wyatt, M. D., & Pittman, D. L. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060164e · Cited by 487
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 468
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger, O., Tutt, A. N. J., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 471
Self-citation
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465
Strategies for optimizing the response of cancer and normal tissues to radiation
Moding, E. J., Kastan, M. B., & Kirsch, D. G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4003 · Cited by 474
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A. G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2121 · Cited by 479
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 472
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 460
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M. V., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 450
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M. R., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 463
Self-citation
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 467
Self-citation
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R. D., van den Bosch, B. J. C., Paulussen, A. D. C., Xanthoulea, S., Blok, M. J., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 472
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 461
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 455
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cruz, C., Castroviejo‐Bermejo, M., Gutiérrez‐Enríquez, S., Llop‐Guevara, A., Ibrahim, Y. H., Gris‐Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 454
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 442
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 446
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Lin, K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I. L., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 449
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., et al. (2011) · Science · doi:10.1126/science.1212728 · Cited by 451
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 436
Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins
Ahel, I., Ahel, D., Matsusaka, T., Clark, A. J., Pines, J., Boulton, S. J., & West, S. C. (2008) · Nature · doi:10.1038/nature06420 · Cited by 429
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 434
Self-citation
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T. A., Kerkhoven, R. M., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 431
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 433
Self-citation
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
Lipkowitz, S., & Weissman, A. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3120 · Cited by 422
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 424
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 402
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
O'Reilly, E. M., Lee, J. W., Zalupski, M. M., Capanu, M., Park, J., Golan, T., Tahover, E., Lowery, M. A., Chou, J. F., Sahai, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02931 · Cited by 420
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7672 · Cited by 399
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsPreprint
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M., Nguyen, H. D., Ho, C. K., Kwan, T. T., Morris, R. T., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 405
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Clarke, N. W., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., Redfern, C. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 405
BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ
Litman, R., Peng, M., Jin, Z., Zhang, F., Zhang, J., Powell, S., Andreassen, P. R., & Cantor, S. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.004 · Cited by 396
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 411
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 403
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
Hanzlíková, H., Kalasová, I., Demin, A. A., Pennicott, L. E., Cihlářová, Z., & Caldecott, K. W. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.004 · Cited by 407
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 394
Molecular pathogenesis of Fanconi anemia: recent progress
Taniguchi, T., & D’Andrea, A. D. (2006) · Blood · doi:10.1182/blood-2005-10-4240 · Cited by 390
Fanconi anaemia and cancer: an intricate relationship
Nalepa, G., & Clapp, D. W. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.116 · Cited by 399
DNA repair targeted therapy: The past or future of cancer treatment?
Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., & Turchi, J. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.003 · Cited by 404
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Bono, J. S. D., Ramanathan, R. K., Mina, L. A., Chugh, R. K., Glaspy, J. A., Rafii, S., Kaye, S. B., Sachdev, J. C., Heymach, J. V., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 390
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Banerjee, S., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00531-3 · Cited by 404
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Plummer, R., Jones, C., Middleton, M. R., Wilson, R. H., Evans, J., Olsen, A. L., Curtin, N. J., Boddy, A. V., McHugh, P. J., Newell, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 389
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“In 2005, two pre-clinical researches published in nature indicated that BRCA1 or BRCA2 deficient cells highly sensitized to PARP inhibition (Farmer et al., 2005; Bryant et al., 2005).”
Background
Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
D’Andrea, A. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809889 · Cited by 390
The fate of chemoresistance in triple negative breast cancer (TNBC)
O'Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Ho, M., Weiner‐Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F. M., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 387
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Llobet, S. G., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 386
DNA Damage/Repair Management in Cancers
Alhmoud, J. F., Woolley, J. F., Moustafa, A. A., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 410
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Ferraris, D. V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100012m · Cited by 380
Regulation of DNA‐damage responses and cell‐cycle progression by the chromatin remodelling factor CHD4
Polo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y., & Jackson, S. P. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.188 · Cited by 374
Self-citation
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Hennessy, B. T., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 376
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 390
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Self-citation
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 384
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Zatreanu, D. A., Robinson, H. M. R., Alkhatib, O., Boursier, M. L., Finch, H., Geo, L., Grande, D., Grinkevich, V. V., Heald, R. A., Langdon, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23463-8 · Cited by 384
Self-citation
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
53BP1: pro choice in DNA repair
Zimmermann, M., & de Lange, T. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.003 · Cited by 387
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 369
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
RETRACTED: Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation
Kaidi, A., Weinert, B. T., Choudhary, C., & Jackson, S. P. (2010) · Science · doi:10.1126/science.1192049 · Cited by 366
Self-citation
Retracted
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Self-citation
Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers
Schwertman, P., Bekker‐Jensen, S., & Mailand, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.58 · Cited by 368
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 389
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
Zhou, J., Gelot, C., Pantelidou, C., Li, A. Y., Yücel, H., Davis, R. E., Färkkilä, A., Kochupurakkal, B. S., Syed, A., Shapiro, G. I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00203-x · Cited by 362
Next-generation sequencing for cancer diagnostics: a practical perspective.
Meldrum, C. J., Doyle, M., & Tothill, R. W. (2011) · Europe PMC (PubMed Central) · Cited by 356
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 360
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Apostolou, P., & Fostira, F. (2013) · BioMed Research International · doi:10.1155/2013/747318 · Cited by 379
New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
Banerjee, S. N., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 368
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 362
Fusogenic Reactive Oxygen Species Triggered Charge‐Reversal Vector for Effective Gene Delivery
Liu, X., Xiang, J., Zhu, D., Jiang, L., Zhou, Z., Tang, J., Liu, X., Huang, Y., & Shen, Y. (2015) · Advanced Materials · doi:10.1002/adma.201504288 · Cited by 354
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A. E., & Djamgoz, M. B. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 355
Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome
Zhang, Y., Wang, J., Ding, M., & Yu, Y. (2013) · Nature Methods · doi:10.1038/nmeth.2603 · Cited by 352
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 363
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 351
DNA helicases involved in DNA repair and their roles in cancer
Brosh, R. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3560 · Cited by 361
Gene expression analysis identifies global gene dosage sensitivity in cancer
Fehrmann, R. S. N., Karjalainen, J. M., Krajewska, M., Westra, H.-J., Maloney, D., Simeonov, A., Pers, T. H., Hirschhorn, J. N., Jansen, R. C., Schultes, E. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3173 · Cited by 347
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 365
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Cong, K., Peng, M., Kousholt, A. N., Lee, W. T. C., Lee, S., Nayak, S. U., Krais, J. J., VanderVere-Carozza, P. S., Pawelczak, K. S., Calvo, J. A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.06.011 · Cited by 360
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Callén, E., Virgilio, M. D., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H. T., Faryabi, R. B., Polato, F., Santos, M. A., Starnes, L. M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.023 · Cited by 356
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 350
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
Goode, E. L., Cancer), T. A. C. S. (., The Australian Ovarian Cancer Study Group, Chenevix‐Trench, G., Song, H., Ramus, S. J., Notaridou, M., Lawrenson, K., Widschwendter, M., Vierkant, R. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.668 · Cited by 341
Massively parallel assessment of human variants with base editor screens
Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.012 · Cited by 316
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 345
Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
Couch, F. J., Nathanson, K. L., & Offit, K. (2014) · Science · doi:10.1126/science.1251827 · Cited by 347
The comings and goings of PARP-1 in response to DNA damage
Pascal, J. M. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.022 · Cited by 355
Biomarkers for Homologous Recombination Deficiency in Cancer
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy085 · Cited by 329
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 351
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition
Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G. L. M., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.005 · Cited by 352
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2)
Pommier, Y. G., Huang, S.-Y. N., Gao, R., Das, B. B., Murai, J., & Marchand, C. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.03.020 · Cited by 347
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S. K., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 345
Self-citation
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2014) · Cancer · doi:10.1002/cncr.28914 · Cited by 329
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H. H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 327
Self-citation
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Fok, J. H. L., Ramos‐Montoya, A., Vázquez–Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N. H., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 352
Translating cancer research into targeted therapeutics
Bono, J. S. D., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 336
Self-citation
The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 347

Authors: Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A.
Affiliations: Cancer Research UK (GB)
Institute of Cancer Research (GB)
Guy's Hospital (GB)
University of Cambridge (GB)
Corresponding author: Smith, Graeme C. M.
Ashworth, Alan
ORCID: Lord, Christopher J.
Tutt, Andrew N. J.
Santarosa, Manuela
Hickson, Ian
Martin, Niall M. B.
Jackson, Stephen P.
Smith, Graeme C. M.
Ashworth, Alan
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04
Volume: 434
Issue: 7035
Pages: 917-921
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03445
OpenAlex: W1973268287
Cited by: 6,683
References: 24
Citations by year: 2026: 271 · 2025: 346 · 2024: 356 · 2023: 454 · 2022: 443 · 2021: 502 · 2020: 460 · 2019: 382 · 2018: 381 · 2017: 353 · 2016: 358 · 2015: 315 · 2014: 312 · 2013: 292 · 2012: 262
FWCI: 68.30
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: Cancer Research UK
National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: BRCA1, BRCA2, PARP inhibitors, homologous recombination, base excision repair, synthetic lethality, breast cancer, DNA double-strand break repair, chromosomal instability, cell cycle arrest, apoptosis, targeted cancer therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cell Survival, DNA Damage, DNA Repair, Mice, Nude, Models, Biological, Mutation, Neoplasms, Poly(ADP-ribose) Polymerases, Substrate Specificity, Apoptosis, Genes, BRCA1, Xenograft Model Antitumor Assays, Genes, BRCA2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks